RT Journal Article
SR Electronic
T1 GILENYA PATIENT CHARACTERISTICS IN THE UK
JF Journal of Neurology, Neurosurgery & Psychiatry
JO J Neurol Neurosurg Psychiatry
FD BMJ Publishing Group Ltd
SP e1
OP e1
DO 10.1136/jnnp-2016-315106.149
VO 87
IS 12
A1 Gordon Mazibrada
A1 Paula Pamies Garcia-Ganuza
YR 2016
UL http://jnnp.bmj.com/content/87/12/e1.56.abstract
AB Background Fingolimod (Gilenya) is a sphingosine 1-phosphate receptor modulator. Fingolimod was first granted a European license in multiple sclerosis in 2011 and first approved for use in the UK by the National Institute for Health and Care Excellence (NICE) in 2012 for patients with highly active relapsing remitting multiple sclerosis (RRMS).MSFine is an observational, retrospective study with the aim to evaluate patient characteristics and clinical outcomes at 12 months post-treatment in patients receiving Gilenya for RRMS in UK clinical practice.Objective To describe the baseline patient characteristics in MSFine and adherence to treatment over the first 12 months of Gilenya therapy.Methodology Retrospective review of patient notes. 11 centers recruited 209 patients.Results 209 patients were recruited. Mean age of patients: 42.4 years. 72.2% female. Baseline EDSS: 3.62. Patient disposition: 62.2% patients had received only 1 disease modifying therapy (DMT) prior to Gilenya; 22% patients treated with ≥2 DMTs before Gilenya and 15.8% patients treated with natalizumab prior to Gilenya. 91.9% of patients remain on treatment after 1 year. Reasons for discontinuation and list of prior DMTs will be reported.Conclusion More than 65% of patients escalated to Gilenya after first failure of DMT. 91.9% of patients commencing on Gilenya in the UK in real world clinical practice remained on treatment after 1 year.